SCHEMBL20178504

SCHEMBL20178504

CC(C)Cc1ccc2cc(C(C)C)cnc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 1/20 0.39
▸ GABRA1 P14867 1/20 0.38
▸ GABRB2 P47870 1/20 0.38
▸ HTR2A P28223 2/20 0.37
▸ HTR2C P28335 1/20 0.37
▸ HTR2B P41595 1/20 0.37
▸ ALOX5AP P20292 1/20 0.36
▸ PDE10A Q9Y233 3/20 0.34
▸ PTGS1 P23219 3/20 0.33
▸ PTGS2 P35354 3/20 0.33
▸ LMNA P02545 2/20 0.33
▸ CYP2C9 P11712 2/20 0.33
▸ AKR1C3 P42330 2/20 0.33
▸ CXCR1 P25024 2/20 0.33
▸ CXCR2 P25025 2/20 0.33
▸ S1PR1 P21453 1/20 0.33
▸ S1PR3 Q99500 1/20 0.33
▸ ALB P02768 1/20 0.33
▸ ESR1 P03372 1/20 0.33
▸ ALOX5 P09917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20049318 0.85 AKR1C3 (0.43) PDE10AAKR1C3NFKB1AKR1C2NPC1
SCHEMBL29297673 0.85 ABL1 (0.44) ABL1GABRA1GABRB2HTR2AHTR2C
SCHEMBL23420196 0.81 ABL1 (0.39) ABL1GABRA1GABRB2HTR2AHTR2C
SCHEMBL11322091 0.79 OGA (0.40) PDE10APTGS1LMNANPC1RAB9A
SCHEMBL7994356 0.79 GAA (0.44) GABRA1GABRB2PTGS1LMNAAKR1C3
SCHEMBL23939714 0.79 HTR2A (0.40) HTR2AHTR2CHTR2BS1PR1S1PR3
SCHEMBL23841158 0.79 HTR2A (0.38) HTR2AHTR2CHTR2BALOX5APPDE10A
SCHEMBL22134831 0.77 CYP1A2 (0.42) ABL1GABRA1GABRB2PDE10ALMNA
SCHEMBL2667927 0.76 ALDH1A1 (0.47) PDE10A
SCHEMBL20012979 0.76 PDGFRB (0.37) HTR2AHTR2CHTR2BALOX5APNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 — — US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 ABL1 2441/4885GABRA1 364/4885GABRB2 479/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 ABL1 2441/4885GABRA1 364/4885GABRB2 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback